A protein secreted into the airways, called SPLUNC1, may be a sensitive biomarker of both mild pulmonary exacerbations and treatment…
Articles by Steve Bryson, PhD
Children with cystic fibrosis (CF) who began taking Orkambi (lumacaftor/ivacaftor) between ages 2 and 5 showed improved height,…
Zinc may be key to reducing bacterial infections in people with cystic fibrosis (CF), researchers at the University of…
A European Medicines Agency (EMA) committee recommends extending the label for Kalydeco (ivacaftor) to children with cystic fibrosis…
A pooled analysis of data from multiple clinical trials of more than 1,100 people with cystic…
The first volunteer has been dosed in a Phase 1 clinical trial evaluating SION-109, an experimental oral treatment for cystic…
Various social and environmental factors in different locations across the U.S. influenced a decline in lung function among adolescents and…
The total cost of managing cystic fibrosis (CF) — healthcare costs, patient and caregiver costs, as well as costs…
At-home telemonitoring of lung function in children with cystic fibrosis (CF) can detect the early onset of pulmonary exacerbations,…
Fas, a protein that triggers programmed cell death, was identified as a potential urinary biomarker for kidney injury associated with…